证券代码：600222 证券简称：太龙药业 公告编号：临 2025-051 河南太龙药业股份有限公司 河南太龙药业股份有限公司（以下简称"公司"）持股 5%以 上股东郑州众生实业集团有限公司（以下简称"众生实业"）持有公 司无限售流通股 50,000,000 股，均处于质押状态，占公司总股本的 8.71%。 截至本公告披露日，众生实业持有公司股份累计被冻结（含轮 候冻结）和司法标记数量为 50,000,000 股，占其持股总数的 100%， 请广大投资者注意投资风险。 众生实业非公司控股股东或第一大股东及其一致行动人，该事 项不会导致公司控制权发生变更。 近日，公司收到持股 5%以上股东众生实业在中国证券登记结算 有限责任公司查询取得的《中国证券登记结算有限责任公司投资者证 券冻结信息（沪市）》，获悉其所持公司股份被轮候冻结/司法标记， 具体情况如下： 关于持股 5%以上股东股份被轮候冻结及司法标记的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 一、本次股份被轮候冻结、司法标记的基本情况 股东名称 冻结 ...

Market Overview - On October 13, the Henan state-owned enterprise reform sector declined by 0.17% compared to the previous trading day, with Yicheng New Energy leading the decline [1] - The Shanghai Composite Index closed at 3889.5, down 0.19%, while the Shenzhen Component Index closed at 13231.47, down 0.93% [1] Stock Performance - The top-performing stock in the Henan state-owned enterprise reform sector was Yuguang Jinchang, which rose by 10.04% to a closing price of 14.58, with a trading volume of 1.1053 million shares and a transaction value of 1.537 billion [1] - Other notable performers included Dayou Energy, which increased by 4.41% to 4.50, and Zhongyuan Media, which rose by 1.41% to 12.19 [1] - Conversely, Yicheng New Energy led the decline with a drop of 5.30% to 5.18, followed by Xinxiang Chemical Fiber, which fell by 3.75% to 4.36 [2] Capital Flow Analysis - The Henan state-owned enterprise reform sector experienced a net outflow of 70.4391 million yuan from institutional investors, while retail investors saw a net inflow of 98.8848 million yuan [2] - The capital flow data indicates that Yuguang Jinchang had a net inflow of 165 million yuan from institutional investors, while it faced a net outflow of 101 million yuan from speculative funds [3] - Zhongyuan Media also saw a net inflow of 15.1455 million yuan from institutional investors, despite a net outflow from speculative funds [3]

Core Viewpoint - Tai Long Pharmaceutical announced that the company has no overdue guarantee matters [2] Company Summary - The announcement was made on the evening of September 30 [2] - The company reassured stakeholders regarding its financial obligations and guarantees [2]

证券代码：600222 证券简称：太龙药业 公告编号：2025-050 河南太龙药业股份有限公司 关于为下属全资及控股子公司融资提供担保的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 被担保人名称 | 浙江桐君堂中药饮片有限公司 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 本次担保金额 | 3,000.00 | 万元 | | | | | | | | | | 担 | 保 | 对 | 实际为其提供的担保余额 | 14,610.00 | 万元（含本次） | 象一 | | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | | | | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | | | | | | | | 被担保人名称 | 北京新领先医药科技发展 ...

Core Insights - The traditional Chinese medicine sector saw a slight increase of 0.27% on September 29, with Jilin Aodong leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] Stock Performance - Jilin Aodong (000623) closed at 20.40, with a rise of 6.69% and a trading volume of 477,000 shares, amounting to a transaction value of 956 million yuan [1] - Other notable performers included: - Zhongheng Group (600252) at 2.74, up 3.40% with a volume of 793,500 shares [1] - Tailong Pharmaceutical (600222) at 6.52, up 3.00% with a volume of 226,600 shares [1] - Jinhua Co., Ltd. (600080) at 7.21, up 3.00% with a volume of 125,500 shares [1] Fund Flow Analysis - The traditional Chinese medicine sector experienced a net outflow of 244 million yuan from institutional investors, while retail investors saw a net inflow of 204 million yuan [2] - The main fund inflows and outflows for specific stocks included: - Jilin Aodong had a net inflow of 91.59 million yuan from institutional investors [3] - Yunnan Baiyao saw a net inflow of 26.21 million yuan from institutional investors [3] - Taikang Group (600129) had a net inflow of 6.25 million yuan from institutional investors [3]

Core Viewpoint - The company has extended the financial support agreement with its indirect controlling shareholder, Zhengzhou High-tech Investment Holding Group Co., Ltd., allowing for a borrowing limit of up to 1.2 billion yuan with a maximum interest rate of 4.2% per annum, aimed at supporting the company's operational funding needs [1][2][4]. Group 1: Related Transactions Basic Situation - The company approved a borrowing agreement with High-tech Investment Holding Group, allowing for loans up to 1.2 billion yuan, with an annual interest rate not exceeding 4.2% [1]. - The company has received loans of 419 million yuan and 157 million yuan from High-tech Investment Holding Group at interest rates of 4.0266% and 3.2966% per annum, respectively [1]. Group 2: Related Transactions Progress - The borrowing agreement's validity has been extended by one year, with the interest rate remaining aligned with the financing costs of similar loans from financial institutions [2][3]. - The company confirmed the borrowing terms with High-tech Investment Holding Group, which will continue to support the company financially, with the original borrowing rate applied until the contract's expiration [3]. Group 3: Financial Support Utilization - The financial support from the controlling shareholder is primarily used to supplement the company's operational funds, with no collateral required, enhancing the flexibility of debt financing [4]. - As of the announcement date, the outstanding balance of financial support received from High-tech Investment Holding Group is 284.7252 million yuan [4].

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-049 河南太龙药业股份有限公司 关于接受间接控股股东财务支持暨关联交易的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、关联交易基本情况 河南太龙药业股份有限公司（以下简称"公司"）分别于 2022 年 3 月 23 日、2022 年 4 月 11 日召开第九届董事会第二次会议和 2022 年第二次临时股东大会，审议通过了《关于公司接受间接控股股东财 务支持暨关联交易的议案》，同意公司及公司控股子公司向公司间接 控股股东郑州高新投资控股集团有限公司（以下简称"高新投控"） 借款不超过 12 亿元（三年内可在该额度内循环使用），单笔借款的 年利率原则上不高于 4.2%，借款额度范围内可分笔支取借款。 公司分别于 2022 年 4 月、2022 年 9 月与高新投控签署《统借统 还借款合同》，并收到高新投控向公司提供的 4.19 亿元、1.57 亿元 借款，资金成本分别为 4.0266%/年、3.2966%/年。 为进一步支持公司发展和日常生产经营 ...

Core Points - On September 25, 2023, the company announced the issuance of a total of 400 million yuan in the first phase of ultra-short-term financing bonds for the year 2025 in the interbank bond market [2] Summary by Category Company Actions - The company has issued ultra-short-term financing bonds amounting to 400 million yuan [2] - The issuance is part of the company's financing strategy for the year 2025 [2] Market Context - The bonds were issued in the interbank bond market, indicating the company's engagement with broader financial markets [2] - This move may reflect the company's efforts to optimize its capital structure and manage liquidity [2]

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-048 河南太龙药业股份有限公司 关于 2025 年度第一期超短期融资券发行结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）分别于 2025 年 7 月 1 日、2025 年 7 月 17 日召开第九届董事会第三十二次会议和 2025 年第二次临时股东大会，审议通过了《关于拟申请注册发行超 短期融资券的议案》，同意公司向中国银行间市场交易商协会（以下 简称"交易商协会"）申请注册发行总额不超过（含）人民币 8 亿元 的超短期融资券。具体内容详见公司于 2025 年 7 月 2 日、2025 年 7 月 18 日在上海证券交易所网站（www.sse.com.cn）披露的相关公告。 2025 年 9 月，公司收到交易商协会出具的《接受注册通知书》 （中市协注﹝2025﹞SCP239 号），交易商协会同意接受公司科技创 新债券注册，注册金额为 8 亿元，注册额度自《接受注册通知书》落 款之日起 2 年内有效，公 ...

Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.12% on September 25, with a current price of 6.46 CNY per share and a market capitalization of 3.707 billion CNY [1] Company Overview - TaiLong Pharmaceutical, established on August 31, 1998, and listed on November 5, 1999, is located in Zhengzhou, Henan Province. The company operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The revenue composition of TaiLong Pharmaceutical includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - As of June 30, 2025, the number of shareholders is 40,900, a decrease of 11.14%, with an average of 14,037 circulating shares per person, an increase of 12.53% [2] Financial Performance - For the first half of 2025, TaiLong Pharmaceutical reported a revenue of 762 million CNY, a year-on-year decrease of 17.77%, and a net profit attributable to shareholders of 19.35 million CNY, down 27.32% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.53 million CNY distributed over the past three years [3] Shareholder Information - As of June 30, 2025, the seventh largest circulating shareholder is Guangfa Pension Index A, holding 3.236 million shares as a new shareholder, while Huatai-PineBridge CSI Traditional Chinese Medicine ETF has exited the top ten circulating shareholders [3]